141 related articles for article (PubMed ID: 27236121)
1. Safety and efficacy of oral factor-Xa inhibitors versus Vitamin K antagonist in patients with non-valvular atrial fibrillation: Meta-analysis of phase II and III randomized controlled trials.
Garg J; Chaudhary R; Krishnamoorthy P; Palaniswamy C; Shah N; Bozorgnia B; Natale A
Int J Cardiol; 2016 Sep; 218():235-239. PubMed ID: 27236121
[TBL] [Abstract][Full Text] [Related]
2. Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation.
Bruins Slot KM; Berge E
Cochrane Database Syst Rev; 2013 Aug; (8):CD008980. PubMed ID: 23925867
[TBL] [Abstract][Full Text] [Related]
3. Uninterrupted direct oral anticoagulants vs. uninterrupted vitamin K antagonists during catheter ablation of non-valvular atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials.
Romero J; Cerrud-Rodriguez RC; Diaz JC; Michaud GF; Taveras J; Alviz I; Grupposo V; Cerna L; Avendano R; Kumar S; Kirchhof P; Natale A; Di Biase L
Europace; 2018 Oct; 20(10):1612-1620. PubMed ID: 29982383
[TBL] [Abstract][Full Text] [Related]
4. Meta-analysis of risk of stroke and thrombo-embolism with rivaroxaban versus vitamin K antagonists in ablation and cardioversion of atrial fibrillation.
Nairooz R; Sardar P; Pino M; Aronow WS; Sewani A; Mukherjee D; Paydak H; Maskoun W
Int J Cardiol; 2015; 187():345-53. PubMed ID: 25839640
[TBL] [Abstract][Full Text] [Related]
5. Minimally interrupted novel oral anticoagulant versus uninterrupted vitamin K antagonist during atrial fibrillation ablation.
De Heide J; Vroegh CJ; Bhagwandien RE; Wijchers SA; Szili-Torok T; Zijlstra F; Lenzen MJ; Yap SC
J Interv Card Electrophysiol; 2018 Dec; 53(3):341-346. PubMed ID: 30074120
[TBL] [Abstract][Full Text] [Related]
6. Comparative Effectiveness and Safety of Apixaban and Vitamin K Antagonist Therapy in Patients With Nonvalvular Atrial Fibrillation Treated in Routine German Practice.
Coleman CI; Peacock WF; Antz M
Heart Lung Circ; 2018 Mar; 27(3):390-393. PubMed ID: 28528780
[TBL] [Abstract][Full Text] [Related]
7. Patients with non-valvular atrial fibrillation on vitamin k antagonists or direct-acting oral anticoagulants: patients profile and long-term follow up outcomes.
Sigismondi A; Camacho-Freire SJ; León-Jiménez J; Isasti-Aizpurva G; García-Lizana MD; Morgado-García de Polavieja JI; Caro-Fernández FJ; Roa-Garrido J; Navarro-Roldán F; Díaz-Fernández JF
Arch Cardiol Mex; 2019; 89(4):382-392. PubMed ID: 31834326
[TBL] [Abstract][Full Text] [Related]
8. Safety and Efficacy of Vitamin K Antagonists versus Rivaroxaban in Hemodialysis Patients with Atrial Fibrillation: A Multicenter Randomized Controlled Trial.
De Vriese AS; Caluwé R; Van Der Meersch H; De Boeck K; De Bacquer D
J Am Soc Nephrol; 2021 Jun; 32(6):1474-1483. PubMed ID: 33753537
[TBL] [Abstract][Full Text] [Related]
9. A meta-analysis of phase III randomized controlled trials with novel oral anticoagulants in atrial fibrillation: comparisons between direct thrombin inhibitors vs. factor Xa inhibitors and different dosing regimens.
Providência R; Grove EL; Husted S; Barra S; Boveda S; Morais J
Thromb Res; 2014 Dec; 134(6):1253-64. PubMed ID: 25457584
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M
Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338
[TBL] [Abstract][Full Text] [Related]
11. Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation.
Cappato R; Marchlinski FE; Hohnloser SH; Naccarelli GV; Xiang J; Wilber DJ; Ma CS; Hess S; Wells DS; Juang G; Vijgen J; Hügl BJ; Balasubramaniam R; De Chillou C; Davies DW; Fields LE; Natale A;
Eur Heart J; 2015 Jul; 36(28):1805-11. PubMed ID: 25975659
[TBL] [Abstract][Full Text] [Related]
12. Rationale and design of AXAFA-AFNET 5: an investigator-initiated, randomized, open, blinded outcome assessment, multi-centre trial to comparing continuous apixaban to vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation.
Di Biase L; Callans D; Hæusler KG; Hindricks G; Al-Khalidi H; Mont L; Cosedis Nielsen J; Piccini JP; Schotten U; Kirchhof P
Europace; 2017 Jan; 19(1):132-138. PubMed ID: 28130378
[TBL] [Abstract][Full Text] [Related]
13. Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: a subgroup analysis of a randomized trial.
Mahaffey KW; Wojdyla D; Hankey GJ; White HD; Nessel CC; Piccini JP; Patel MR; Berkowitz SD; Becker RC; Halperin JL; Singer DE; Califf RM; Fox KA; Breithardt G; Hacke W
Ann Intern Med; 2013 Jun; 158(12):861-8. PubMed ID: 23778903
[TBL] [Abstract][Full Text] [Related]
14. Direct Oral Anticoagulants Versus Vitamin-K Antagonist After PCIs in Patients With AF: A Meta-analysis of Cardiac Ischemic Events.
Cordero A; Ferreiro JL; Bertomeu-González V; Rodríguez-Mañero M; Fácila L; Escribano D; Sanchez-Recalde A; Zuazola P; Ruiz-Nodar JM; González-Juanatey JR
J Cardiovasc Pharmacol; 2021 Feb; 77(2):164-169. PubMed ID: 33351537
[TBL] [Abstract][Full Text] [Related]
15. The safety and efficacy of vitamin K antagonist in patients with atrial fibrillation and liver cirrhosis.
Lee SJ; Uhm JS; Kim JY; Pak HN; Lee MH; Joung B
Int J Cardiol; 2015 Feb; 180():185-91. PubMed ID: 25463361
[TBL] [Abstract][Full Text] [Related]
16. Clinical impact of major bleeding in patients with venous thromboembolism treated with factor Xa inhibitors or vitamin K antagonists. An individual patient data meta-analysis.
Bleker SM; Brekelmans MPA; Eerenberg ES; Cohen AT; Middeldorp S; Raskob G; Büller HR
Thromb Haemost; 2017 Oct; 117(10):1944-1951. PubMed ID: 28816341
[TBL] [Abstract][Full Text] [Related]
17. [Efficacy and safety of non-vitamin K antagonist versus vitamin K antagonist oral anticoagulants in the prevention and treatment of thrombotic disease in active cancer patients: a systematic review and meta-analysis of randomized controlled trials].
Wang CX; Wu D; Yang PP; Wu QH
Zhonghua Xin Xue Guan Bing Za Zhi; 2020 Aug; 48(8):689-696. PubMed ID: 32847326
[No Abstract] [Full Text] [Related]
18. Comparative efficacy and safety of the non-vitamin K antagonist oral anticoagulants for patients with nonvalvular atrial fibrillation.
Senoo K; Lip GY
Semin Thromb Hemost; 2015 Mar; 41(2):146-53. PubMed ID: 25682085
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of apixaban compared with aspirin in patients who previously tried but failed treatment with vitamin K antagonists: results from the AVERROES trial.
Coppens M; Synhorst D; Eikelboom JW; Yusuf S; Shestakovska O; Connolly SJ
Eur Heart J; 2014 Jul; 35(28):1856-63. PubMed ID: 24569032
[TBL] [Abstract][Full Text] [Related]
20. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation.
Cappato R; Ezekowitz MD; Klein AL; Camm AJ; Ma CS; Le Heuzey JY; Talajic M; Scanavacca M; Vardas PE; Kirchhof P; Hemmrich M; Lanius V; Meng IL; Wildgoose P; van Eickels M; Hohnloser SH;
Eur Heart J; 2014 Dec; 35(47):3346-55. PubMed ID: 25182247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
